clinical trial · NCT07482657
A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus
Enanta Pharmaceuticals, Inc·phase2·not yet recruiting·n = 150
RSV InfectionRSVRespiratory Syncytial Virus (RSV)zelicapavirPlacebo
brief summary
Zelicapavir is a novel, orally administered, nonfusion replication inhibitor of RSV. It is being investigated in this Phase 2 study (EDP 938-203) as a potential treatment for RSV infection in both hospitalized and non-hospitalized children aged ≥28 days to ≤36 months who present with symptomatic RSV infection.
started
Jul 1, 2026
primary completion
Dec 1, 2026
completion
Dec 1, 2026
last updated
Mar 19, 2026
official title
Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zelicapavir in Participants ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol